The $14.6m round was co-led by distribution partner Fosun Pharma and also featured existing investor Baidu Ventures,

China-based prosthetic joint surgery robot producer Jianjia closed a series B round co-led by Fosun Pharma, the healthcare products arm of conglomerate Fosun, at more than RMB100m ($14.6m) on Monday.

GL Ventures, a venture capital arm of investment firm Hillhouse Capital, co-led the round, which included Baidu Ventures, a corporate venturing subsidiary of internet group Baidu. Investment bank Haoyue Capital was financial adviser.

Founded in 2018, Jianjia has created a robotic system called Arthrobot which helps surgeons place prosthetic joint…